In the ever-evolving landscape of healthcare and medical technology, a select group of public innovative companies is emerging as the vanguards of change, determined to reshape the way we approach health and well-being. These visionary companies are not only making waves but also transforming lives through their groundbreaking endeavors. In this article, we'll go in more depth on four promising stocks in the healthcare and medical technology.
APPYEA, Inc. (OTC: APYP) - AppYea is a Health-tech firm focused on bringing to market an innovative wearable technology designed to address snoring issues, while simultaneously working on the development of wearable solutions aimed at diagnosing and treating sleep apnea. The company's offerings leverage their exclusive intellectual property portfolio, featuring AI and sensing technologies, to monitor and analyze breathing patterns, vital signs, and various physiological parameters during sleep. These solutions are engineered to provide heightened precision at a more budget-friendly and accessible price point. AppYea Inc's wholly-owned subsidiary, SleepX, is an Israeli research and development firm that has created a distinctive solution for monitoring and addressing sleep apnea and snoring. The combined organization will emphasize advancing and bringing these products to the market, with its strategy encompassing ongoing investment in research and development as well as the introduction of fresh sales and marketing initiatives. On August 28, 2023, AppYea Inc announced that it has received a patent (US 11,672,472 B2) from the United States Patent and Trademark Office, bearing the title: "Techniques and Systems for Assessing Obstructive Sleep Apnea Severity in Awake Individuals via Multiple Speech Analyses." This patent remains in effect until November 2038 and offers comprehensive protection within the realm of sleep apnea monitoring. We'll monitor this one for continued upside or potentially another update from the company.
--
Therma Bright Inc. (OTC: TBRIF) - Therma Bright is at the forefront of developing and collaborating on cutting-edge, exclusive diagnostic and medical device technologies. These technologies are centered on delivering innovative solutions to consumers and healthcare practitioners, addressing critical challenges in the medical and healthcare sectors. Therma Bright's primary focus is on three strategic domains: Respiratory Disease, Vascular Health, and Consumer Medical Devices. The company is dedicated to developing, acquiring, manufacturing, and promoting proprietary healthcare and medical devices within both consumer and institutional markets. On September 7, 2023, Therma Bright made an announcement regarding the submission of an updated application to the U.S. Food and Drug Administration (FDA) for 510K clearance. This submission aims to rectify the intended use, labeling, and product description of the Venowave device to align better with the requirements of the U.S. Centers for Medicare and Medicaid Services (CMS) application for permanent Current Procedural Terminology (CPT®) and Healthcare Common Procedure Coding System (HCPCS) codes. The company anticipates sharing additional details as they become available, including information about the distinct permanent CPT® and HCPCS codes, as well as its plans to expand its network of distribution partners throughout the United States for the Venowave device. An estimated 20 million Americans suffer from PAD. Unfortunately, about 200,000 of these patients, disproportionately people of color, suffer avoidable amputations every year. Therma Bright believes that the Venowave technology may assist patients in an early prevention program to prevent amputations. Currently sitting around .03 per share while sitting at bottom, we'll monitor this one for a potential move to the upside.
--
AINOS Inc. (NASADQ: AIMD) - Ainos is a versatile healthcare enterprise with a concentration on pioneering advancements in point-of-care testing (POCT), low-dose VELDONA interferon therapeutics, and synthetic RNA-driven preventive healthcare solutions. The company's product range encompasses clinical-stage human therapeutics known as VELDONA, cytoprotein health supplements for pets under the VELDONA Pet brand, and telehealth-compatible POCTs driven by its AI Nose technology platform. Their recognition of the success of messenger RNA (mRNA) COVID-19 vaccines has inspired them to envision a bright future for synthetic RNA (SRNA) in accelerating pharmaceutical innovation. They are in the process of establishing a synthetic RNA (SRNA) technology platform that can manufacture messenger RNAs (mRNAs) and/or short inhibitory RNAs (siRNAs) to explore potential applications in vaccine development and disease treatment.
On September 5, 2023, Ainos made an announcement regarding the initiation of shipments for its VELDONA® Pet cytoprotein supplements in Taiwan. Mr. Chun-Hsien (Eddy) Tsai, who serves as Chairman of the Board, President, and Chief Executive Officer of Ainos, expressed his satisfaction with the favorable feedback received from customers. The company is currently in the process of producing 300,000 units of VELDONA® Pet and anticipates concluding deliveries in October to meet the demands of its initial orders. Currently sitting at $0.60 a share, put this one on your radar for a potential bounce in the near future.
--
RemSleep Holdings, Inc. (OTC: RMSL) - RemSleep Holdings, Inc. is a medical device manufacturer committed to revolutionizing the standard of care for individuals with obstructive Sleep Apnea. Their primary emphasis lies in the design and production of devices and solutions tailored for addressing Sleep Apnea and related respiratory ailments. With a cumulative experience of more than three decades in CPAP therapy, the REMSleep team possesses profound insights into CPAP technology and the hurdles associated with patient adherence. Their unwavering dedication is directed toward developing products that have a meaningful impact and enhance the well-being of individuals afflicted by Sleep Apnea. On September 1, 2023, RemSleep Holdings issued an update regarding its testing procedure concerning the DeltaWave CPAP Mask's 510K clearance. RemSleep has successfully concluded the testing protocol for 510K clearance, and all examinations, including the Cytotoxicity and MLA tests that previously necessitated retesting, have passed without issue. Initially, the company projected a timeline of 3-6 weeks for collating these outcomes. However, RemSleep has now revised this estimate to 2-4 weeks before submitting the results to the FDA for 510K clearance. Keep an eye on this one for potential updates from the company in the near future.
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. We have been retained by a third party, Cambridge Consulting, to assist in the production and distribution of content. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content.
AppYea, Inc. is a digital health company, which is focused on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring and fundamentally improve quality of life. The Companyâs business plan focuses on two principal devices and an App in development: DreamIT and DreamIT PRO, and SleepX PRO. DreamIT is a biofeedback snoring treatment wristband, combined with the SleepX App and this wristband uses algorithms designed by SleepX combined with sensors to monitor physiological parameters during sleep. DreamIT PRO is a wristband for the treatment of sleep apnea using biofeedback in combination with the SleepX PRO app. The algorithms of SleepX PRO, combined with the wristband sensors, monitor sleep apnea events and additional physiological parameters during sleep, and when necessary. SleepX PRO is a medical application that is used to monitor breathing patterns in sleep and identify sleep apnea episodes without direct contact with the user.
APPYEA, INC. 
